Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03687346 · ClinicalTrials.gov registry record

Biological Risk Factors for Onset of Binge Eating and Compensatory Behaviors

A clinical trial of Eating Disorder, sponsored by Oregon Research Institute.

Completed
Registry status
88
Enrollment target
1
Study location

NCT03687346: Completed study of Eating Disorder, sponsored by Oregon Research Institute.

NCT03687346 is a study of Eating Disorder that has completed, run by Oregon Research Institute. The registered enrollment target is 88 participants, below the 110-participant average among 9 other Eating Disorder trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03687346, a study of Eating Disorder, has completed, sponsored by Oregon Research Institute.

COMPLETED
Registry status
88 participants
Enrollment target
1
Study location

Study Summary

The purpose of this proposed project is to test whether several biological factors (such as elevated brain reward region and attention region response to high-calorie foods, weaker inhibitory region response to high-calorie foods, habitual caloric deprivation, and elevated limbic region responsivity) increase the risk of problematic eating (bingeing and purging) in female adolescents.

Primary Outcome

Eating Disorder Diagnostic Interview (EDDI)

Conditions Studied

Study Locations (1)

Oregon

  • Oregon Research Institute - Eugene

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2017-08-03
Est. Completion 2021-10-01
Oregon Research Institute

62 total trials

What the finished NCT03687346 record still lists

NCT03687346 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 110-participant average among 9 other Eating Disorder trials with a reported enrollment target (20% lower).

The record links to 1 condition, with Eating Disorder appearing as the primary indexed condition, and to 0 interventions.

NCT03687346 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT03687346 about?

NCT03687346 is a clinical study titled "Biological Risk Factors for Onset of Binge Eating and Compensatory Behaviors". The purpose of this proposed project is to test whether several biological factors (such as elevated brain reward region and attention region response to high-calorie foods, weaker inhibitory region response to high-calorie foods, habitual caloric deprivation, and elevated limbic region responsivity...

What is the current status of trial NCT03687346?

This trial is currently completed. The enrollment target is 88 participants. The study started on 2017-08-03. Estimated completion is 2021-10-01.

What conditions does trial NCT03687346 study?

This clinical trial studies the following conditions: Eating Disorder.

Who is sponsoring clinical trial NCT03687346?

This trial is sponsored by Oregon Research Institute, which has 62 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03687346 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Eating Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03687346's enrollment target sits among peer trials

88 4th of 9 higher than 5 of 9 other Eating Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Eating Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03843463 · 88 participants · Phase 2

    Escitalopram and Language Intervention for Subacute Aphasia

  • NCT04066348 · 88 participants · Phase 2

    TNF-α Treatment of Blast-Induced Tinnitus

  • NCT04331704 · 88 participants · Phase 4

    ANCHORS Alcohol & Sexual Health Study: UH3 Project

  • NCT04536103 · 88 participants

    Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03687346, the US trial registry maintained by the National Library of Medicine. NCT03687346 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.